The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.» Read More
The Supreme Court is weighing ending financial aid to HealthCare.gov customers in 34 states.
Two divergent U.S. core inflation readings could be related to the price of medical care. CNBC explores.
Twitter may be able to help control disease outbreaks even in developing countries in Africa, a study suggests.
A short set of questions have been put together to let the middle-aged know whether they need to make plans after 2020.
A new blood test can find just about every virus you ever caught—in a single drop of blood, NBC News reports.
Hospitals are increasingly tracking and using their own online doctor rating systems to improve patient satisfaction.
A bird flu vaccine doesn't work well enough to approve it for emergency use against the current outbreak, the U.S. Department of Agriculture said.
A major Texas health insurer is feeling "blue" from some steep losses and now wants sharply higher prices for Obamacare plans next year.
South Korea's Health Ministry confirmed five additional cases of Middle East Respiratory Syndrome (MERS) on Thursday, raising the total to 35.
The CDC said doctors and state health officials should be on the lookout for people infected with the H5N2 bird flu virus, NBC reports.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
The figures are in: HealthCare.gov has about 6.4 million paying customers who are at risk of losing subsidies in a pending Supreme Court case.
South Korea confirmed five more cases of Middle East Respiratory Syndrome (MERS), bringing to 30 the number of infected people. Two people have died.
Many of the proposed rate increases of 10 percent or more for Obamacare health insurance plans have been revealed.
Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.
As a stock market analyst, Janet Yellen makes a pretty good Federal Reserve chair.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
The "Halftime Report" traders give their trades for the second half.
Proposals to deal with a potential Supreme Court ruling could merely delay serious disruption to the insurance market.
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Get the best of CNBC in your inbox